Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions.

Damelin M, Bankovich A, Bernstein J, Lucas J, Chen L, Williams S, Park A, Aguilar J, Ernstoff E, Charati M, Dushin R, Aujay M, Lee C, Ramoth H, Milton M, Hampl J, Lazetic S, Pulito V, Rosfjord E, Sun Y, King L, Barletta F, Betts A, Guffroy M, Falahatpisheh H, O'Donnell CJ, Stull R, Pysz M, Escarpe P, Liu D, Foord O, Gerber HP, Sapra P, Dylla SJ.

Sci Transl Med. 2017 Jan 11;9(372). pii: eaag2611. doi: 10.1126/scitranslmed.aag2611.

PMID:
28077676
2.

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.

Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, Desai R, Escarpe PA, Hampl J, Laysang A, Liu D, Lopez-Molina J, Milton M, Park A, Pysz MA, Shao H, Slingerland B, Torgov M, Williams SA, Foord O, Howard P, Jassem J, Badzio A, Czapiewski P, Harpole DH, Dowlati A, Massion PP, Travis WD, Pietanza MC, Poirier JT, Rudin CM, Stull RA, Dylla SJ.

Sci Transl Med. 2015 Aug 26;7(302):302ra136. doi: 10.1126/scitranslmed.aac9459.

3.

Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions.

Damelin M, Bankovich A, Park A, Aguilar J, Anderson W, Santaguida M, Aujay M, Fong S, Khandke K, Pulito V, Ernstoff E, Escarpe P, Bernstein J, Pysz M, Zhong W, Upeslacis E, Lucas J, Lucas J, Nichols T, Loving K, Foord O, Hampl J, Stull R, Barletta F, Falahatpisheh H, Sapra P, Gerber HP, Dylla SJ.

Clin Cancer Res. 2015 Sep 15;21(18):4165-73. doi: 10.1158/1078-0432.CCR-15-0695. Epub 2015 May 26.

4.

Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients.

Collarini EJ, Lee FE, Foord O, Park M, Sperinde G, Wu H, Harriman WD, Carroll SF, Ellsworth SL, Anderson LJ, Tripp RA, Walsh EE, Keyt BA, Kauvar LM.

J Immunol. 2009 Nov 15;183(10):6338-45. doi: 10.4049/jimmunol.0901373. Epub 2009 Oct 19.

5.

Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.

Bornstein GG, Quéva C, Tabrizi M, van Abbema A, Chavez C, Wang P, Foord O, Ahluwalia K, Laing N, Raja S, Wen S, Green LL, Yang X, Webster C, Stewart R, Blakey D.

Invest New Drugs. 2010 Oct;28(5):561-74. doi: 10.1007/s10637-009-9291-z. Epub 2009 Jul 21.

PMID:
19626278
6.

A novel method of Multiplexed Competitive Antibody Binning for the characterization of monoclonal antibodies.

Jia XC, Raya R, Zhang L, Foord O, Walker WL, Gallo ML, Haak-Frendscho M, Green LL, Davis CG.

J Immunol Methods. 2004 May;288(1-2):91-8.

PMID:
15183088
7.

Expression and characterization of glycogen synthase kinase-3 mutants and their effect on glycogen synthase activity in intact cells.

Eldar-Finkelman H, Argast GM, Foord O, Fischer EH, Krebs EG.

Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10228-33.

8.

Long-distance PCR.

Foord OS, Rose EA.

PCR Methods Appl. 1994 Jun;3(6):S149-61. No abstract available.

9.
10.

In search of the functions of normal p53 protein.

Rotter V, Foord O, Navot N.

Trends Cell Biol. 1993 Feb;3(2):46-9.

PMID:
14731719
11.

A DNA binding domain is contained in the C-terminus of wild type p53 protein.

Foord OS, Bhattacharya P, Reich Z, Rotter V.

Nucleic Acids Res. 1991 Oct 11;19(19):5191-8.

Supplemental Content

Support Center